Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ivy Rx vs Medro

Ivy Rx
Graded #178

Higher grade

vs+3.1999999999999957
Medro
Graded #252

Lower grade

The verdict

Ivy Rx takes it — 66.8/100 to 63.6/100.

Ivy Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telehealth provider offering tiered compounded semaglutide and tirzepatide programs.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueIvy Rx +12
62
50
Dose & formulationMedro +13
64
77
Clinical oversightIvy Rx +11
82
71
Labs & monitoringIvy Rx +1
53
52
FulfillmentMedro +11
81
92
Contract termsIvy Rx +22
55
33
Ivy Rx · left barMedro · right bar

The numbers

MetricIvy RxMedro
WeighScore66.8/10063.6/100
GradeCC
Scorecard rank#178#252
Semaglutide$175/mo (starting dose, compounded)$199/mo (compounded)
Tirzepatide$275/mo (starting dose, compounded)$299/mo (compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Ivy Rx

Graded #178 · C

Strengths

  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details
Medro

Graded #252 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard